Novozymes A/S (OTCMKTS:NVZMY) Shares Shorted: Short Interest Down 95.5% in September

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 546 shares, a drop of 95.5% from the September 15th total of 12,081 shares. Based on an average trading volume of 47,865 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Institutional Trading of Novozymes A/S

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its position in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Novozymes A/S Price Performance

Shares of NVZMY traded up $0.97 during trading hours on Friday, reaching $65.26. 24,343 shares of the company’s stock traded hands, compared to its average volume of 24,596. Novozymes A/S has a 12 month low of $49.90 and a 12 month high of $75.27. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 0.25. The stock has a market cap of $27.05 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89. The firm’s 50 day simple moving average is $66.64 and its 200-day simple moving average is $62.75.

Novozymes A/S (OTCMKTS:NVZMY) last posted its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.27 billion. Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%. Equities analysts expect that Novozymes A/S will post 2.45 EPS for the current year.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing.